• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高钙透析液在肾性骨软化症治疗中的应用。

The use of high calcium dialysate in the treatment of renal osteomalacia.

作者信息

Evans R A, Somerville P J

出版信息

Aust N Z J Med. 1976 Feb;6(1):10-5. doi: 10.1111/j.1445-5994.1976.tb03284.x.

DOI:10.1111/j.1445-5994.1976.tb03284.x
PMID:1065293
Abstract

Four chronic haemodialysis patients suffering from osteomalacia were treated by increasing their dialysate calcium concentration from 1-40 to 2-15 mM/I. Bone biopsies were taken before and after 22 weeks of this treatment and a further biopsy was taken in one patient after 52 weeks. Symptomatic cure occurred in one patient with mild osteomalacia and some improvement osteomalacia and hyperparathyroidism. Bone biopsies showed slight improvement in the patient with mild osteomalacia after 22 weeks, and considerable improvement after 25 weeks. In the patient with mixed histology, the osteitis fibrosa subsided and the osteomalacia became a little worse after 22 weeks. There was no histologic improvement in the two patients with severe osteomalacia after 22 weeks. It is concluded that high calcium dialysis is not an effective treatment for renal osteomalacia.

摘要

4例患有骨软化症的慢性血液透析患者接受了治疗,方法是将透析液钙浓度从1.40mmol/L提高到2.15mmol/L。在该治疗22周前后进行了骨活检,并且在1例患者52周后又进行了一次活检。1例患有轻度骨软化症的患者症状得到治愈,另外一些患者的骨软化症和甲状旁腺功能亢进有所改善。骨活检显示,轻度骨软化症患者在22周后有轻微改善,25周后有显著改善。在组织学表现混合的患者中,骨纤维炎在22周后消退,但骨软化症稍有加重。2例患有严重骨软化症的患者在22周后组织学上没有改善。结论是高钙透析不是治疗肾性骨软化症的有效方法。

相似文献

1
The use of high calcium dialysate in the treatment of renal osteomalacia.高钙透析液在肾性骨软化症治疗中的应用。
Aust N Z J Med. 1976 Feb;6(1):10-5. doi: 10.1111/j.1445-5994.1976.tb03284.x.
2
Histopathology of renal osteodystrophy with particular reference to the effects of 1alpha-hydroxyvitamin D3 in patients treated by long-term haemodialysis.肾性骨营养不良的组织病理学,特别提及长期血液透析患者中1α-羟维生素D3的作用
Clin Endocrinol (Oxf). 1977 Dec;7 Suppl:31s-38s. doi: 10.1111/j.1365-2265.1977.tb03359.x.
3
[Renal osteodystrophy (3); its treatment in dialysis patients].[肾性骨营养不良(3);透析患者的治疗]
Nephrologie. 2000;21(8):413-24.
4
Renal osteodystrophy.
Curr Ther Endocrinol Metab. 1994;5:504-8.
5
Iliac bone marrow mast cells in relation to the renal osteodystrophy of patients treated by haemodialysis.与接受血液透析治疗患者的肾性骨营养不良相关的髂骨髓肥大细胞
J Clin Pathol. 1976 Jun;29(6):502-16. doi: 10.1136/jcp.29.6.502.
6
Renal osteodystrophy--pathogenesis and treatment.肾性骨营养不良——发病机制与治疗
Am J Med Sci. 1985 Dec;290(6):234-45. doi: 10.1097/00000441-198512000-00003.
7
Osteomalacia in patients with chronic renal failure before dialysis or transplantation.
Q J Med. 1983 Summer;52(207):332-48.
8
Review: Renal osteodystrophy--pathogenesis and treatment.综述:肾性骨营养不良——发病机制与治疗
Am J Med Sci. 1986 Apr;291(4):264-75. doi: 10.1097/00000441-198604000-00008.
9
Azotaemic renal osteodystrophy: a quantitative study on iliac bone.氮质血症性肾性骨营养不良:髂骨的定量研究。
J Clin Pathol. 1973 Feb;26(2):83-101. doi: 10.1136/jcp.26.2.83.
10
Management of bone disease in the dialysis patient.
Blood Purif. 1985;3(1-3):27-41. doi: 10.1159/000169396.